247 related articles for article (PubMed ID: 21262787)
1. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9.
Ason B; Tep S; Davis HR; Xu Y; Tetzloff G; Galinski B; Soriano F; Dubinina N; Zhu L; Stefanni A; Wong KK; Tadin-Strapps M; Bartz SR; Hubbard B; Ranalletta M; Sachs AB; Flanagan WM; Strack A; Kuklin NA
J Lipid Res; 2011 Apr; 52(4):679-87. PubMed ID: 21262787
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH).
Muntoni S; Pisciotta L; Muntoni S; Bertolini S
J Clin Lipidol; 2015; 9(1):103-6. PubMed ID: 25670367
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.
Torimoto K; Okada Y; Mori H; Hajime M; Tanaka K; Kurozumi A; Narisawa M; Yamamoto S; Arao T; Matsuoka H; Inokuchi N; Tanaka Y
Lipids Health Dis; 2013 Sep; 12():137. PubMed ID: 24053480
[TBL] [Abstract][Full Text] [Related]
4. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials.
Catapano A; Brady WE; King TR; Palmisano J
Curr Med Res Opin; 2005 Jul; 21(7):1123-30. PubMed ID: 16004682
[TBL] [Abstract][Full Text] [Related]
5. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
6. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
Yamazaki D; Ishida M; Watanabe H; Nobori K; Oguma Y; Terata Y; Koyama T; Iino K; Kosaka T; Ito H
Lipids Health Dis; 2013 Feb; 12():9. PubMed ID: 23374898
[TBL] [Abstract][Full Text] [Related]
7. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
[TBL] [Abstract][Full Text] [Related]
8. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
Bays HE; Averna M; Majul C; Muller-Wieland D; De Pellegrin A; Giezek H; Lee R; Lowe RS; Brudi P; Triscari J; Farnier M
Am J Cardiol; 2013 Dec; 112(12):1885-95. PubMed ID: 24063830
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial.
Awan Z; Seidah NG; MacFadyen JG; Benjannet S; Chasman DI; Ridker PM; Genest J
Clin Chem; 2012 Jan; 58(1):183-9. PubMed ID: 22065156
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
[TBL] [Abstract][Full Text] [Related]
14. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
[TBL] [Abstract][Full Text] [Related]
15. Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Rosen JB; Jimenez JG; Pirags V; Vides H; Massaad R; Hanson ME; Brudi P; Triscari J
Lipids Health Dis; 2013 Jul; 12():103. PubMed ID: 23866306
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia.
Kanazawa I; Yamaguchi T; Yamauchi M; Sugimoto T
Intern Med; 2009; 48(21):1869-73. PubMed ID: 19881236
[TBL] [Abstract][Full Text] [Related]
18. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
[TBL] [Abstract][Full Text] [Related]
19. The future direction of cholesterol-lowering therapy.
Evans M; Roberts A; Rees A
Curr Opin Lipidol; 2002 Dec; 13(6):663-9. PubMed ID: 12441891
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
